Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

• Published in: International Journal of Obesity Vol. 40; no. 8; pp. 1310 - 1319
• Main Authors: Blackman, A, Foster, G D, Zammit, G, Rosenberg, R, Aronne, L, Wadden, T, Claudius, B, Jensen, C B, Mignot, E
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.08.2016; Nature Publishing Group
• Subjects: 631/92/436/108; 692/163; 692/699/2743/393; 692/699/375/1816; 692/700/2817; 692/700/565/1903; Adolescent; Adult; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Appetite depressants; Blood pressure; Body mass index; Body weight; Clinical medicine; Clinical practice guidelines; Clinical trials; Complications and side effects; Diabetes; Double-Blind Method; Drug dosages; Drug therapy; Epidemiology; Exercise; Female; Glycated Hemoglobin A - metabolism; Health Promotion and Disease Prevention; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Internal Medicine; Liraglutide; Liraglutide - pharmacology; Liraglutide - therapeutic use; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Middle Aged; Obesity; Obesity - complications; Obesity - drug therapy; Obesity - physiopathology; Original; original-article; Physical fitness; Polysomnography; Prospective Studies; Public Health; Quality of life; Sleep apnea; Sleep apnea syndromes; Sleep Apnea, Obstructive - complications; Sleep Apnea, Obstructive - drug therapy; Sleep Apnea, Obstructive - physiopathology; Treatment Outcome; United States - epidemiology; Weight control; Weight Loss - drug effects; Young Adult; Denmark; Canada; United States; New York; United States > US

Background: Obesity is strongly associated with prevalence of obstructive sleep apnea (OSA), and weight loss has been shown to reduce disease severity. Objective: To investigate whether liraglutide 3.0 mg reduces OSA severity compared with placebo using the primary end point of change in apnea–hypop...